CA2700172A1 - Antimicrobial gas-releasing ear drainage tubes - Google Patents

Antimicrobial gas-releasing ear drainage tubes Download PDF

Info

Publication number
CA2700172A1
CA2700172A1 CA2700172A CA2700172A CA2700172A1 CA 2700172 A1 CA2700172 A1 CA 2700172A1 CA 2700172 A CA2700172 A CA 2700172A CA 2700172 A CA2700172 A CA 2700172A CA 2700172 A1 CA2700172 A1 CA 2700172A1
Authority
CA
Canada
Prior art keywords
gas
antimicrobial
releasing
resin material
nitric oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2700172A
Other languages
French (fr)
Inventor
Yossef Av-Gay
David Greenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enox Biopharma Inc
Original Assignee
Enox Biopharma, Inc.
Yossef Av-Gay
David Greenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enox Biopharma, Inc., Yossef Av-Gay, David Greenberg filed Critical Enox Biopharma, Inc.
Publication of CA2700172A1 publication Critical patent/CA2700172A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • A61F11/20Ear surgery
    • A61F11/202Surgical middle-ear ventilation or drainage, e.g. permanent; Implants therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002Implant devices for drainage of body fluids from one part of the body to another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/114Nitric oxide, i.e. NO
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45Mixtures of two or more drugs, e.g. synergistic mixtures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/14Materials or treatment for tissue regeneration for ear reconstruction or ear implants, e.g. implantable hearing aids

Abstract

A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane.
The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas.
The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.

Description

ANTIMICROBIAL GAS-RELEASING EAR DRAINAGE TUBES
TECHNICAL FIELD

This invention relates to ear drainage tubes. More particularly, this invention relates to gas-releasing antimicrobial ear drainage tubes.
BACKGROUND ART

Installation of tympanostomy tubes for the treatment of otitis media with effusion or in patients with recurrent events of acute otitis media, is a commonly performed surgical procedure in North America and elsewhere. In this procedure an incision is made in the tympanic membrane, fluid from within the middle ear is aspirated and a tympanostomy tube is inserted. The tubes can have various configurations and materials, and are effective in correcting the hearing loss due to the effusion as long as the tubes are in place in the ear.
The materials which can be used to make tympanostoray tubes include thermoplastics such as modified elastomers and olefins, thermosets such as silicone and polytetrafluoroethylene; and metals such as stainless steel and titanium. Children with persistent middle ear effusions who do not respond to antibiotics undergo a procedure in which a myringotomy is performed in the tympanic membrane under local anesthesia. However the implantation of the tympanostomy tubes also be done under general anesthesia.

Purulent otorrhea frequently develops after tube insertion. In one study by H. G. Birck and J. J. Mravek "Myringotomy for Middle Ear Effusions,"
Ann. of Otol. Rhino. Laryngo., volume 85, pages 263-267 (1979), the investigators observed that 15% of children having tympanostomy tubes inserted in their ears following myringotomy developed postoperative otorrhea.
In a more recent study by George A. Gates et al, "Post Tympanostomy Otorrhea," Laryngoscope, volume 96, pages 630-634, (June 1986), the investigators observed that the incidence of tympanostomy tube induced otorrhea following myringotomy was 18%. In a clinical study performed by Balkany et al, "A Prospective Study of Infection Following Tympanostomy and Tube Insertion," American Journal of Otology, volume 4, pages 288-291
2 (1983), the investigators observed an incidence of postoperative otorrhea of 19% in children receiving tympanostomy tubes with no antibiotic drops postoperatively applied. In the Balkany et al study, the investigators found that the incidence of postoperative otorrhea was reduced to 6% when antibiotic drops were put into the patient's ear after myringotomy. In another study on the use of antibiotics after myringotomy, R. S. Baker and R. A. Chole, "A
Randomized Clinical Trial of Topical Gentamicia After Tympanostomy Tube Placement," Arch. Otolaryngology Head and Neck Surgery, volume 114, pages, 755-757 (July 1988), the investigators found that the incidence of infections in the experimental group using Gentamicin, an ophthalmic solution used as otic drops, had an incidence of infection significantly reduced by antibiotic drops.
In both the Balkany et al and Baker et al studies using antibiotic drops after tympanostomy, the investigators used potentially ototoxic antibiotics, namely Cortisporin and Gentamicin. Based on their frequency of use, and the lack of adverse effects noted in these studies, antibiotic drops are now used routinely to prevent postoperative otorrhea. However, thorough studies demonstrating the absence of adverse toxicological reaction in the use of antibiotic drugs for the treatment of postoperative otorrhea have not been published.

In addition to the relatively high incidence of otorrhea after myringotomy, investigators have observed children with implanted tympanostomy tubes sometimes experience bouts of otorrhea. Occasionally, the otorrhea became persistent causing some investigators to believe that the tympanostomy tubes become colonized with pathogenic bacteria.

The relatively high incidence of otorrhea after myringotomy and tympanostomy tube insertion exposes patients with persistent middle ear effusions to significant morbidity and additional treatment time and cost.

It would be desirable to utilize tympanostomy tubes whereby the incidence of otorrhea and other microbial induced infection after myringotomy and tympanostomy tube insertion could be substantially reduced without the
3 use of antibiotics and the potential ototoxic reaction associated with the use of such drugs.

One approach for reducing bacterial infection encountered with the use of medical devices inserted into body cavities has been to apply an antimicrobial coating to the surface of the medical device. For example, U.S.
Pat. No. 4,592,920 to Murtfeldt; U.S. Pat. No. 4,603,152 to Laurin et al and U.S. Pat. No. 4,677,143 to Laurin et al each teach applying a coating containing an antimicrobial agent such as silver oxide to the outer surfaces of medical devices such as catheters, enteral feeding tubes, endotracheal tubes and other hollow tubular devices.

U.S. Patent No. 4,592,920 to Murtfeldt is primarily concerned with providing a surface coating of an antimicrobial metal compound on a medical device such as a catheter, but also discloses that the metal compound can be "imbedded" within the entire catheter. However, the Murtfeldt patent finds the imbedded construction to be less desirable since the antimicrobial metal compound imbedded within the side wall of the catheter has less likelihood of encountering migrating microbes and by inference is less effective than a surface coating.

U.S Patent No. 6,361,526 provides a tube formed from a thermoset resin containing therein between 0.5 to 15% by weight of a selected antimicrobial metal oxide compounds exemplified by silver oxide, that are capable of migrating to the sidewall surfaces of the tube. Such metal oxide-laden antimicrobial resin-based tubes are generally produced by controllably intermixing a selected metal oxide into a thermoset resin paste that is subsequently milled, then formed into a hollow tube by conventional tube-forming processes.

DISCLOSURE OF THE INVENTION

The exemplary embodiments of the present invention, are directed to antimicrobial gas-permeable gas-releasing conduits suitable for surgical implantation into and through patients' tympanic membranes. Suitable gas-
4 permeable conduits are exemplified by tympanostomy tubes, myringotomy tubes and the like.

According to one aspect, the cured gas-permeable gas-releasing resin material comprises curable silicones.

According to another aspect, the antimicrobial gas-permeable gas-releasing molecules are exemplified by nitric oxide (NO) molecules.

According to another aspect the NO gas-permeable gas-releasing implantable conduits are coated with NO-releasing compositions exemplified by those having N202. functional groups, NO-releasing intramolecular salts, and S-nitrosothiols among others.

According to further aspect, the antimicrobial gas-permeable gas-releasing conduits are exemplified by tympanostomy tubes.

According to a further aspect, the antimicrobial gas-permeable gas-releasing conduits are exemplified by myringotomy tubes.

According to another exemplary embodiment of the present invention, the antimicrobial gas-permeable gas-releasing conduits are produced with a process whereby fully configured and cured gas-permeable resin-based tubes are controllably saturated with a selected antimicrobial gas exemplified by NO, whereby the resin-based tubes releasably sequester NO gas molecules. The antimicrobial gas-saturated conduits are individually packaged in gas-impermeable containers.

According to one aspect, the resin-based conduits sequestering therein NO gas molecules, are coated with NO-releasing compositions exemplified by those having N2O2- functional groups, NO-releasing intramolecular salts, and S-nitrosothiols among others.

According to a further embodiment, the antimicrobial gas-releasing conduits are produced by intermixing a suitable selected chelating agent saturated with antimicrobial gas molecules, with a curable polymeric resin material. The intermixed material is formed and configured into a plurality of antimicrobial gas-releasing conduits, then cured. After curing, the antimicrobial gas-releasing conduits are individually packaged and sealed into gas-impermeable containers.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be described in conjunction with reference to
5 the following drawings, in which:

Fig. 1(a) is a chart showing the effects of gNO released from gNO-charged vent tubes on the proliferation of Streptococcus pyogenes. Fig 1(b) is a chart showin the effects of released gNO on survival of S. pyogenes;

Fig. 2(a) is a chart showing the effects of gNO released from gNO-charged vent tubes on the proliferation of Streptococcus pneumonia. Fig 2(b) is a chart showin the effects of released gNO on survival of S. pneumonia;

Fig. 3(a) is a chart showing the effects of gNO released from gNO-charged vent tubes on the proliferation of Moraxella catarrhalis. Fig 3(b) is a chart showin the effects of released gNO on survival of M. catarrhalis;

Fig. 4(a) is a chart showing the effects of gNO released from gNO-charged vent tubes on the proliferation of Haemophilus influenzae. Fig 4(b) is a chart showin the effects of released gNO on survival of H. influenzae;

Fig. 5(a) is a chart showing the effects of gNO released from gNO-charged vent tubes on the proliferation of methicillin-resistant Staphylococcus aureus. Fig 5(b) is a chart showin the effects of released gNO on survival of S.
aureus; and Fig. 6 is a chart showing the effects of gNO released from gNO-charged silicon vent tubes and gNO-charged polytetrafluoroethylene vent tubes on the proliferation of Staphylococcus aureus.

DETAILED DESCRIPTION OF THE INVENTION

The exemplary embodiments of the present invention are directed to antimicrobial conduit structures configured for long-term installation through
6 the tympanic membranes into the inner ear cavities for the purpose of draining fluids therefrom. Such conduit structures are exemplified by tympanostomy tubes, myringotomy ventilation tubes and the like, and will be generally referred to from hereon in as "tympanostomy tubes". The antimicrobial tympanostomy tubes according to the present invention generally comprise materials that are controllably permeatable with gases selected for their antimicrobial properties.

The antimicrobial tympanostomy tubes of the present invention are characterized by their biological compatibility with otologic tissue associated with the tympanic membrane and middle ear tissues, and generally comprise polymeric materials exemplified by resins which after forming and curing, are microporous and have the requisite high gas permeability properties needed to prepare the antimicrobial tympanostomy tubes of the present invention. These resins are suitably characterized by an ability for infiltratably sequestering selected permeating antmicrobial gases, and then controllably releasing the antimicrobial gases over extended periods of time. Suitable resins are exemplified by curable silicones, polyvinyl acetates, thermoplastic elastomers, acrylonitrile-butadiene-styrene copolymer rubber, polyurethanes and the like.
Curable silicone resins are preferred for the manufacture of the antimicrobial tympostomy tubes of the present invention due to their molecular structure which provides good flexibility both microscopically and macroscopically, and high gas permeability rates. Table I illustrates the gas permeability of silicone resins in comparison with other types of materials suitable for such tubular manufacture.

The geometries of the antimicrobial tympanostomy tubes are generally cylindrical and may simply comprise elongate hollow conduits having the same diameter extending from end to end, or alternatively may comprise elaborate configurations that may additionally include abrupt diameter changes and odd shaped flanges.
7 Table 1: Gas permeation through selected materials (cc/0.001in/100.0 in2/24 h at 22.8 C, 0% relative humidity, ASTM D-1434)*.

Permeatin gas Tubular material 02 CO2 Silicone 50,000 300,000 Urethanes 200 3,000 Epoxies 5-10 8 Fluorocarbons 7-15 15-30 Nylon 2.6 4.7 Pol but lene 385 825 Polycarbonate 258 775 Cellulose acetate 23 105 * adapted from; (1) Packaging Encyclopedia 1988 Vol. 33 No. 5, pp. 54-55, and Machine Design, May 25, 1967, p. 192.

Gaseous nitric oxide (gNO) is an intermediary compound produced during the normal functioning of numerous biochemical pathways in many biological systems including humans. gNO is known to those skilled in these arts as a key biological messenger signaling compound that plays key roles in many biological processes. Recent evidence (e.g., Ghaffari et al., 2005 Nitric Oxide 14: 21-29) suggests that gNO plays an important role in mammalian host defense against infection and regulates wound healing and angiogenesis. In particular, topical applications of exogenous gNO at 200 ppm for extended periods of time inhibited and prevented the growth of a wide range of microbial pathogens Staphylococcus aureus, Escherichia coli, Group B Streptococcus, Pseudomonas aeruginosa, and Candida albicans, without any cytotoxic effects on cultured human dermal fibroblasts. Furthermore, McMullin et al. (2005, Respir. Care 5:1451-1456) demonstrated that exogenous gNO at a concentration of 200 ppm could clear nosocomial pneumonia caused by microbial pathogens such as S. aureus and P. aeruginosa, in about 6 hours.
Accordingly, gNO is a particularly suitable antimicrobial gas for saturatingly permeating tympanostomy tubes comprising gas-permeable polymeric materials.

The antimicrobial typanostomy tubes of the present invention are produced by first casting a desired tubular configuration with a selected suitable resin using conventional methods known to those skilled in these arts. It is
8 suitable to process the tubes into their final configuration and finish after which, the tubes are placed into a sealable chamber. The chamber is then saturated with a selected antimicrobial gas, exemplified by gNO, for a selected period of time suitable for infiltratingly saturating the tympanostomy tubes whereby the gas is sequestered into and within the resin structure comprising the tubes thereby by providing antimicrobial properties to the tympanostomy tubes. Excess gNO is then evacuated from the chamber after which, the gNO-loaded tympanostomy tubes are removed and individually packaged into gas-impermable containers.
It is within the scope of the present invention to infiltrate the chamber with a semi-porous sealing gaseous material configured to at least partially cross-link with the outer surfaces antimicrobial tympanostomy tubes thereby enabling a further extension of time duration for release of the sequestered gas about the antimicrobial tympanostomy tubes. The chamber may be controllably infiltrated with the semi-porous sealing gaseous material concurrently with evacuation of the antimicrobial gas from the chamber or alternatively, the antimicrobial gas may be completely evacuated from the chamber after which, the semi-porous sealing gaseous material may be infiltrated into the chamber. Excess semi-porous sealing gaseous material is then evacuated from the chamber after which, the gNO-loaded tympanostomy tubes are removed and individually packaged into gas-impermable containers.

It is also within the scope of the present invention to incorporate gNO-sequestering chelating agents into a suitable selected resin material prior to forming tympanostomy tubes. Suitable gNO-sequestering chelating agents are exemplified by sodium nitrite, nitrosothiols, dipyridoxyl chelating agents, L-arginine, organic nitrates, organic nitrites, thionitrates, thionitrites, N-oxo-N-nitrosamines, N-nitrosamines, sydnonimines,2- hydroxyimino-5-nitro-alkenamides, diazenium diolates, oxatriazolium compounds, oximes, syndomines, molsidomine and derivatives thereof, pirsidomine, furoxanes, nitrosonium salts, and the like, and combinations thereof. A suitable amount of a selected gNO-sequestering chelating agent is placed into a sealable chamber which is then saturated with gNO. A suitable amount of the gNO-loaded chelating agent is then thoroughly intermixed and commingled with a selected resin material after which, the resin material is processed into tympanostomy
9 tubes using methods known to those skilled in these arts. The tympanostomy tubes comprising interspersed therethrough gNO-loaded chelating agent, are then sealably packaged into gas-impermeable containers.

It is also within the scope of the present invention to provide an antimicrobial gas-releasing coating onto the outer surfaces, and optionally on to the innter surfaces, of NO gas-permeated tympanostomy tubes of the present invention. For example, NO gas-releasing coatings can be provided by applying to the NO gas-permeated tympanostomy tubes, a composition comprising a N202_ functional group that will bind to the cured resin material comprising the tympanostomy tubes. Suitable exemplary compounds comprising N202- functional groups are disclosed in US Patent Number 5,525,357. Other suitable exemplary coating compositions for providing NO
gas-releasing coatings onto NO gas-permeated tympanostomy tubes include among others, NO-releasing intramolecular salts known as zwitterions having the general formula 2RN[N(O)NO-(CH2),NH2+R', and S-nitrosothiols.

An antimicrobial gas-permeated tympanostomy tube of the present invention can be surgically implanted using well-known procedures, through a patient's tympanic membrane such that one end of the tympanostomy tube extends into the patient's middle ear cavity while the other end of the tube extends through the tympanic membrane into the outer ear cavity. The antimicrobial gas sequestered within the resin material comprising the implanted tympanostomy tube will slowly diffuse from and about the tube thereby alleviating and/or preventing post-operative microbial infections normally associated with these types of tubes and without adverse toxicology reactions exemplified by irritation and inflammation, of otologic tissues.
Contact with moisture will expedite the release of gNO sequestered within and coated onto the antimicrobial tympanostomy tubes of the present invention.
Furthermore, provision of NO gas-releasing coatings on the outer surfaces of the tubes, and optionally on their inner surfaces, will inhibit and prevent the formation of biofilms thereon.

EXAMPLES

A plurality of vent tubes comprising a polytetrafluoroethylene (PTFE) substrate (1.25 mm Sheehy collar buttons, catalog number 23-40300; Inovotec 5 International Inc., Jacksonville, FL, USA) were placed into gas-ventable Petri dishes. A suitable cather was used to connect the Petri dishes to a manifold connected to a cylinder containing gNO manufactured by Airgas (Chicago 11, USA). The manifold was provided with a gas flow controller adjusted to deliver 22,000 ppm of gNO to each Petri dish at a flow rate of 30 cc min-' for a period
10 of 22 h. After the gNO-charging process was completed, the gNO-charged PTFE vent tubes were stored in gas-impermeable containers. All handling of the vent tubes after the gNO-charging process was completed, was done using aseptic techniques.

Stock cultures of Streptococcus pyogenes (ATCC# 51878), Streptococcus pneumonia (ATCC# 10015), Moraxella catarrhalis (ATCC#
25240), and Haemophilus influenzae (ATCC# 35540) were maintained on nutrient agar. Broth cultures of each microorganism were prepared by inoculating a test tube containing 10 mL of Brain Heart Infusion broth with a colony picked from a stock culture plate. The inoculated test tubes were cultured for 12 h to 18 h at 37 C in an incubater provided with an atmosphere containing about 5% CO2. The cultures were then diluted with fresh Brain Heart Infusion broth to an OD600 reading of 0.5. Each broth culture thus prepared contained 107 to 108 colony-forming units (CFU) mL-'. All handling of the microbial cultures was done using aseptic techniques.

All wells in a 24-well plate received 1 mL of broth culture of a selected microorganism prepared as described above. Each of 12 wells received 1 gNO-charged PTFE vent tube prepared as described above. Each of the remaining 12 wells received 1 sterile PTFE vent tube as supplied by the manufacturer. The tubes were incubated in the broth cultures contained in the 24-well plates for about I min after which, each tube was removed from its broth culture and transferred to a quadrant in a quadrant Petri dish. The quadrant Petri dishes
11 were maintained for 7 h at 37 C in an incubater provided with an atmosphere containing about 5% CO2. Individual tubes were removed from the quadrant Petri dishes after 3 h and 7 h of incubation, and were each placed into a microtubes containing 30 L of sterile phosphate-buffered saline (PBS) and vortexed. The PBS was then pipetted onto a nutrient agar plate and spread across the agar surface. The inoculated plates were then incubated for 24 h at 37 C in an incubater provided with an atmosphere containing about 5% CO2 after which, the plates were removed and the numbers of CFU units appearing thereon were quantified. The results are shown in Figs. 1-4. The data show that exposure of S. pyogenes (Figs. 1(a) and 1(b)), S. pneumonia (Figs. 2(a) and 2(b)), M. catarrhalis (Figs. 3(a) and 3(b)), and H. influenzae (Figs. 4(a) and 4(b)) to gNO-charged vent tubes reduced the proliferation of each of the microbial species tested.

A plurality of vent tubes comprising a PTFE substrate (Armstrong Beveled vent tube Grommet-type 1.14 mm I.D Fluorplastic, from Gyrus ACMI, catalog number 140242; Inovotec International Inc., Jacksonville, FL, USA) were placed into gas-ventable Petri dishes. A suitable cather was used to connect the Petri dishes to a manifold connected to a cylinder containing gNO
manufactured by Airgas (Chicago 11, USA). The manifold was provided with a gas flow controller adjusted to deliver 22,000 ppm of gNO to each Petri dish at a flow rate of 30 cc min-' for a period of 22 h. After the gNO-charging process was completed, the gNO-charged PTFE vent tubes were stored in gas-impermeable containers. All handling of the vent tubes after the gNO-charging process was completed, was done using aseptic techniques.

A stock culture of methicillin-resistant Staphylococcus aureus (MRSA;
ATCC# 700698), was maintained on nutrient agar. MSRA is a S. aureus strain that is known to be resistant to a number of broad-spectrum antibiotics commonly used to treat it. MRSA broth cultures were prepared by inoculating a plurality of test tubes containing 10 mL of Brain Heart Infusion broth with a colony picked from a stock culture plate. The inoculated test tubes were cultured for 12 h to 18 h at 37 C in an incubater provided with an atmosphere
12 containing about 5% CO2. The cultures were then diluted with fresh Brain Heart Infusion broth to an OD600 reading of 0.5. Each broth culture thus prepared contained about 105 CFU mL-1. All handling of the microbial cultures was done using aseptic techniques.

All wells in a 24-well plate received 1 mL of a MSRA broth culture prepared as described above. Each of 12 wells received 1 gNO-charged PTFE
vent tube prepared as described above. Each of the remaining 12 wells received 1 sterile PTFE vent tube as supplied by the manufacturer. The tubes were incubated in the broth cultures contained in the 24-well plates for about I
min after which, each tube was removed from its broth culture and transferred to a quadrant in a quadrant Petri dish. The quadrant Petri dishes were maintained for 7 h at 37 C in an incubater provided with an atmosphere containing about 5%
CO2. Individual tubes were removed from the quadrant Petri dishes after 3 h and 7 h of incubation, and were each placed into a microtubes containing 30 L
of sterile phosphate-buffered saline (PBS) and vortexed. The PBS was then pipetted onto a nutrient agar plate and spread across the agar surface. The inoculated plates were then incubated for 24 h at 37 C in an incubater provided with an atmosphere containing about 5% CO2 after which, the plates were removed and the numbers of CFU units appearing thereon were quantified. The results are shown in Fig. . The data show that exposure of methicillin-resistant Staphylococcus aureus (Figs. 5(a) and 5(b)) to gNO-charged vent tubes reduced the proliferation of this microbial species.

A first plurality of vent tubes comprising a silicon substrate (T-Tube, Silicon Myringotomy Tube, 23-50600; Invotec International Inc., Jacksonville, FL, US) and a second plurality of vent tubes a PTFE substrate (Sheehy Collar Button, Fluoroplastic Myringotomy Tube, 23-40300; Inovotec International Inc., Jacksonville, FL, USA) were placed into gas-ventable Petri dishes. A
suitable cather was used to connect the Petri dishes to a manifold connected to a cylinder containing gNO manufactured by Airgas (Chicago IL, USA). The manifold was provided with a gas flow controller adjusted to deliver 22,000 ppm of gNO to each Petri dish at a flow rate of 30 cc min- i for a period of 22 h.
13 After the gNO-charging process was completed, the gNO-charged silicon vent tubes and PTFE vent tubes were stored in gas-impermeable containers. All handling of the vent tubes after the gNO-charging process was completed, was done using aseptic techniques.

A stock culture of a Staphylococcus aureus (ATCC# 25923), was maintained on nutrient agar. S. aureus broth cultures were prepared by inoculating a plurality of test tubes containing 10 mL of Brain Heart Infusion broth with a colony picked from a stock culture plate. The inoculated test tubes were cultured for 12 h to 18 h at 37 C in an incubater provided with an atmosphere containing about 5% CO2. The cultures were then diluted with fresh Brain Heart Infusion broth to an OD6oo reading of 0.5. Each broth culture thus prepared contained about 105 CFU mL-1. All handling of the microbial cultures was done using aseptic techniques.

All wells in a 24-well plate received 1 mL of a S. aureus broth culture prepared as described above. Each of 12 wells received 1 gNO-charged PTFE
vent tube prepared as described above. Each of the remaining 12 wells received 1 sterile PTFE vent tube as supplied by the manufacturer. The tubes were incubated in the broth cultures contained in the 24-well plates for about I
min after which, each tube was removed from its broth culture and transferred to a quadrant in a quadrant Petri dish. The quadrant Petri dishes were maintained for 7 h at 370 C in an incubater provided with an atmosphere containing about 5%
CO2. Individual tubes were removed from the quadrant Petri dishes after 3 h and 7 h of incubation, and were each placed into a microtubes containing 30 L
of sterile phosphate-buffered saline (PBS) and vortexed. The PBS was then pipetted onto a nutrient agar plate and spread across the agar surface. The inoculated plates were then incubated for 24 h at 37 C in an incubater provided with an atmosphere containing about 5% CO2 after which, the plates were removed and the numbers of CFU units appearing thereon were quantified. The results are shown in Fig. . The data show that exposure of S. aureus ATCC#
25923 to gNO-charged vent tubes reduced the proliferation of this microbial species on silicon-based vent tubes and on PTFE vent tubes (Fig. 6).
14 While this invention has been described with respect to the exemplary embodiments, it is to be understood that various alterations and modifications can be made to the configurations and shapes of the antimicrobial tympanostomy tubes, and to methods for saturatingly infiltrating the tubes with a selected antimicrobial gas within the scope of this invention, which are limited only by the scope of the appended claims.

Claims (26)

What is claimed is:
1. An antimicrobial gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane, the antimicrobial conduit comprising:

an elongate hollow tube comprising a gas-permeable cured resin material, said gas-permeable cured resin material configured for releasably sequestering therein permeating gases; and a permeating antimicrobial gas releasably sequestered therein said gas-permeable resin material.
2. An antimicrobial conduit according to claim 1, wherein said gas-permeable cured resin material comprises a hydrophobic resin material.
3. An antimicrobial conduit according to claim 1, wherein said gas-permeable cured resin material is selected from the group consisting of curable silicones, polyvinyl acetates, thermoplastic elastomers, acrylonitrile-butadiene-styrene copolymer rubber, polyurethanes and selected combinations thereof.
4. An antimicrobial conduit according to claim 1, wherein said gas-permeable cured resin material is coated with an antimicrobial gas-releasing composition.
5. An antimicrobial conduit according to claim 1, wherein said permeating antimicrobial gas is nitric oxide.
6. An antimicrobial conduit according to claim 4, wherein said antimicrobial gas-releasing composition is configured to release nitric oxide.
7. An antimicrobial conduit according to claim 4, wherein said antimicrobial gas-releasing composition is selected from the group consisting of nitric oxide gas-releasing intramolecular salts, S-nitrosothiols, compounds provided with N2O2- functional groups, and combinations thereof.
8. An antimicrobial conduit according to claim 1, wherein said elongate hollow tube is a tympanostomy tube.
9. An antimicrobial conduit according to claim 1, wherein said elongate hollow tube is a myringotomy tube.
10. A process for producing an antimicrobial gas-releasing conduit suitable for surgical implantation through a patient's tympanic membrane, the process comprising:
placing into a sealable chamber, a plurality of selected conduits comprising a gas-permeable cured resin material, said gas-permeable cured resin material configured for releasably sequestering therein permeating antimicrobial gases;
sealing and then controllably saturating said chamber with a selected antimicrobial gas whereby the antimicrobial gas permeates into and is releasably sequestered therein the gas-permeable cured resin material;
controllably evaculating unsequestered antimicrobial gas from said sealed chamber and then unsealing the chamber; and individually sealing each antimicrobial gas-saturated conduit within a gas-impermeable packaging.
11. A process according to claim 10, wherein said gas-impermeable cured resin comprises a hydrophobic resin material.
12. A process according to claim 10, wherein said gas-impermeable cured resin is selected from the group consisting of curable silicones, polyvinyl acetates, thermoplastic elastomers, acrylonitrile-butadiene-styrene copolymer rubber, polyurethanes and selected combinations thereof.
13. A process according to claim 10, wherein the antimicrobial gas is nitric oxide.
14. The process according to claim 10, wherein said elongate hollow tube is a tympanostomy tube.
15. The process according to claim 10, wherein said elongate hollow tube is a myringotomy tube.
16. The process according to claim 10, wherein said gas-permeable cured resin material sequestering therein a permeating antimicrobial gas, is coated with an antimicrobial gas-releasing composition prior to sealing said antimicrobial gas-saturated conduit within a gas-impermeable packaging.
17. The process according to claim 16, wherein said antimicrobial gas-releasing composition is configured to release nitric oxide gas.
18. The process according to claim 16, wherein said antimicrobial gas-releasing composition is selected from the group consisting of nitric oxide gas-releasing intramolecular salts, S-nitrosothiols, compounds provided with N2O2-functional groups, and combinations thereof.
19. A process for producing a nitric oxide gas-releasing conduit suitable for surgical implantation through a patient's tympanic membrane, the process comprising:

commingling and intermixing a nitric-acid-saturated nitric-acid-chelating compound with a polymeric resin material capable of forming a gas-permeable cured resin;

producing and curing a plurality of nitric oxide gas-releasing conduits from said polymeric resin material intermixed with said nitric-acid-saturated nitric-acid-chelating compound; and individually packaging and sealing said plurality of nitric oxide gas-releasing conduits into gas-impermeable containers.
20. A process according to claim 19, wherein the nitric-acid chelating compound is selected from the group comprising sodium nitrite, nitrosothiols, dipyridoxyl chelating agents, L- arginine, organic nitrates, organic nitrites, thionitrates, thionitrites, N-oxo-N-nitrosamines, N-nitrosamines, sydnonimines,2-hydroxyimino-5-nitro-alkenamides, diazenium diolates, oxatriazolium compounds, oximes, syndomines, molsidomine and derivatives thereof, pirsidomine, furoxanes, nitrosonium salts, and combinations thereof.
21. A process according to claim 19, wherein the polymeric resin material is selected from the group consisting of curable silicones, polyvinyl acetates, thermoplastic elastomers, acrylonitrile-butadiene-styrene copolymer rubber, polyurethanes and combinations thereof.
22. The process according to claim 19, wherein said gas-permeable cured resin material sequestering therein nitric oxide gas, is coated with an antimicrobial gas-releasing composition prior to sealing said nitric oxide gas-releasing conduit within a gas-impermeable packaging.
23. The process according to claim 19, wherein said antimicrobial gas-releasing composition is configured to release nitric oxide gas.
24. The process according to claim 19, wherein said antimicrobial gas-releasing composition is selected from the group consisting of nitric oxide gas-releasing intramolecular salts, S-nitrosothiols, compounds provided with N2O2-functional groups, and combinations thereof.
25. The process according to claim 19, wherein said elongate hollow tube is a tympanostomy tube.
26. The process according to claim 19, wherein said elongate hollow tube is a myringotomy tube.
CA2700172A 2007-09-21 2008-09-19 Antimicrobial gas-releasing ear drainage tubes Abandoned CA2700172A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97422807P 2007-09-21 2007-09-21
US60/974,228 2007-09-21
PCT/CA2008/001658 WO2009036571A1 (en) 2007-09-21 2008-09-19 Antimicrobial gas-releasing ear drainage tubes

Publications (1)

Publication Number Publication Date
CA2700172A1 true CA2700172A1 (en) 2009-03-26

Family

ID=40467460

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2700172A Abandoned CA2700172A1 (en) 2007-09-21 2008-09-19 Antimicrobial gas-releasing ear drainage tubes

Country Status (8)

Country Link
US (4) US8043246B2 (en)
EP (1) EP2195042B1 (en)
KR (1) KR20100087096A (en)
CN (1) CN101835502A (en)
AU (1) AU2008301195A1 (en)
CA (1) CA2700172A1 (en)
MX (1) MX2010003087A (en)
WO (1) WO2009036571A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141863A3 (en) * 2010-05-10 2012-01-05 Enox Biopharma, Inc. Gaseous nitric oxide-sequestering products and processes of preparing same
US10350112B2 (en) 2007-09-21 2019-07-16 Enox (Israel) Ltd. Antimicrobial gas impregnated devices and methods

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606565C (en) 2005-05-27 2016-05-10 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
CN102711729B (en) 2009-08-21 2015-04-01 诺万公司 Topical gels
WO2011022680A2 (en) 2009-08-21 2011-02-24 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US8499764B2 (en) 2010-05-26 2013-08-06 The Invention Science Fund I, Llc Portable apparatus for establishing an isolation field
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (en) 2011-02-28 2019-01-02 Novan Inc Silica particles modified with S-nitrosothiol that release nitric oxide and methods of manufacturing them

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4417576A (en) * 1982-02-25 1983-11-29 Baran Ostap E Double-wall surgical cuff
US4603152A (en) * 1982-11-05 1986-07-29 Baxter Travenol Laboratories, Inc. Antimicrobial compositions
US4592920A (en) * 1983-05-20 1986-06-03 Baxter Travenol Laboratories, Inc. Method for the production of an antimicrobial catheter
US4677143A (en) * 1984-10-01 1987-06-30 Baxter Travenol Laboratories, Inc. Antimicrobial compositions
DE3916648C1 (en) * 1989-05-22 1990-09-06 Fa. Carl Freudenberg, 6940 Weinheim, De
US5236422A (en) * 1991-06-24 1993-08-17 Eplett Jr James D Antiseptic urinary catheter cuff
US5525357A (en) * 1992-08-24 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5519843A (en) 1993-03-15 1996-05-21 M-Systems Flash memory system providing both BIOS and user storage capability
US5417657A (en) * 1993-10-06 1995-05-23 Hauer; Carolyn No-sepsis urinary drainage catheter
US6361526B1 (en) * 1993-11-01 2002-03-26 Medtronic Xomed, Inc. Antimicrobial tympanostomy tube
US5857998A (en) * 1994-06-30 1999-01-12 Boston Scientific Corporation Stent and therapeutic delivery system
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
TW482651B (en) * 1994-12-28 2002-04-11 Baxter Int Antimicrobial materials.
US5820917A (en) * 1995-06-07 1998-10-13 Medtronic, Inc. Blood-contacting medical device and method
US6541363B2 (en) 1996-10-17 2003-04-01 Guobiao Zhang Antifuse manufacturing process
JP4570696B2 (en) 1997-04-10 2010-10-27 ジョンズ・ホプキンズ・ユニバーシティ Gas syringe device
EP1037621A4 (en) 1997-10-15 2004-01-21 Univ Jefferson Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US20070275100A1 (en) 1998-11-23 2007-11-29 Miller Christopher C Use of gaseous nitric oxide as an anti-cancer agent
SE9902207L (en) 1999-06-11 2000-12-12 Sca Hygiene Prod Ab Use of moisture-tight packaging for absorbent articles containing moisture-sensitive additives
US6494862B1 (en) * 1999-07-13 2002-12-17 Advanced Cardiovascular Systems, Inc. Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway
US6261526B1 (en) * 1999-08-12 2001-07-17 Henkel Corporation Nickel recovery process and compositions for use therein
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
US20040009238A1 (en) 2002-07-09 2004-01-15 Chris Miller Exogenenous nitric oxide gas (gNO) therapy in wound healing
US6432077B1 (en) 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
US7179251B2 (en) * 2001-01-17 2007-02-20 Boston Scientific Scimed, Inc. Therapeutic delivery balloon
US6706274B2 (en) 2001-01-18 2004-03-16 Scimed Life Systems, Inc. Differential delivery of nitric oxide
US6656506B1 (en) 2001-05-09 2003-12-02 Advanced Cardiovascular Systems, Inc. Microparticle coated medical device
JP2004538090A (en) * 2001-07-23 2004-12-24 ノボバスキュラー インコーポレーテッド Nitrogen oxide releasing ePTFE coated medical device sandwich
US6841166B1 (en) 2001-08-21 2005-01-11 The Regents Of The University Of Michigan Nitric oxide-releasing polymers incorporating diazeniumdiolated silane derivatives
US6703046B2 (en) 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
GB0125222D0 (en) 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
US6656155B2 (en) * 2001-12-17 2003-12-02 Scimed Life Systems, Inc. Catheter for endoluminal delivery of therapeutic agents that minimizes loss of therapeutic
US20070065473A1 (en) 2002-07-09 2007-03-22 Miller Christopher C Nitric oxide gas (gO) as a cosmetic and wound healing agent
US20030039697A1 (en) * 2002-09-12 2003-02-27 Yi-Ju Zhao Matrices containing nitric oxide donors and reducing agents and their use
CA2481865C (en) 2003-09-24 2011-07-05 Nipro Corporation Hollow fiber blood-processing device and method for packaging and sterilizing such devices
US8017074B2 (en) 2004-01-07 2011-09-13 Noxilizer, Inc. Sterilization system and device
US7090946B2 (en) * 2004-02-19 2006-08-15 Maxwell Technologies, Inc. Composite electrode and method for fabricating same
SE0402221D0 (en) 2004-09-14 2004-09-14 Aerocrine Ab Treatment of insufficient perfusion
US20070154570A1 (en) 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
WO2006078786A1 (en) * 2005-01-18 2006-07-27 Selective Micro Technologies, Llc Antimicrobial gas desorbing articles
ATE407708T1 (en) 2005-02-11 2008-09-15 Nolabs Ab DEVICE AND METHOD FOR TREATING DERMATOMYCOSES AND IN PARTICULAR ONYCHOMYCOSES
WO2006100154A1 (en) 2005-03-24 2006-09-28 Nolabs Ab Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
CA2606565C (en) 2005-05-27 2016-05-10 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
EP1764119A1 (en) * 2005-09-09 2007-03-21 NOLabs AB Implants with improved osteointegration
US8585753B2 (en) * 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
EP2037977A2 (en) * 2006-06-28 2009-03-25 SurModics, Inc. Active agent eluting matrices with particulates
US8079998B2 (en) 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
US20080160064A1 (en) 2006-12-22 2008-07-03 Capelli Christopher C Devices and methods for inhibiting fibrosis
US20080193566A1 (en) 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
EP2142179B1 (en) 2007-03-27 2017-04-26 BSN medical GmbH Topical dermal delivery device for nitric oxide delivery
WO2008148396A2 (en) 2007-06-07 2008-12-11 Mariann Lisbeth Poulsen Tampon
US8043246B2 (en) * 2007-09-21 2011-10-25 Enox Biopharma, Inc. Antimicrobial gas-releasing ear drainage tubes
WO2009049208A1 (en) 2007-10-12 2009-04-16 The University Of North Carolina At Chapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
WO2009124379A1 (en) * 2008-04-09 2009-10-15 Enox Biopharma, Inc. Biofilm-inhibiting catheters and tubings
CA2728789A1 (en) 2008-06-24 2009-12-30 Micropharma Limited Nitric oxide compositions and devices and methods for cosmesis
WO2011141863A2 (en) 2010-05-10 2011-11-17 Enox Biopharma, Inc. Gaseous nitric oxide-sequestering products and processes of preparing same
CA2830298C (en) 2011-03-17 2016-08-16 Transdermal Biotechnology, Inc. Topical nitric oxide systems comprising lecithin and methods of use thereof
CA2835320A1 (en) 2011-05-09 2012-11-15 Topical Therapeutic Agent (Tta) Ltd. Nitric oxide-sequestering topical formulations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350112B2 (en) 2007-09-21 2019-07-16 Enox (Israel) Ltd. Antimicrobial gas impregnated devices and methods
US11337863B2 (en) 2007-09-21 2022-05-24 Enox (Israel) Ltd. Antimicrobial gas impregnated devices and methods
WO2011141863A3 (en) * 2010-05-10 2012-01-05 Enox Biopharma, Inc. Gaseous nitric oxide-sequestering products and processes of preparing same

Also Published As

Publication number Publication date
US20190298575A1 (en) 2019-10-03
AU2008301195A1 (en) 2009-03-26
US20090131883A1 (en) 2009-05-21
US9814623B2 (en) 2017-11-14
CN101835502A (en) 2010-09-15
US10350112B2 (en) 2019-07-16
US8043246B2 (en) 2011-10-25
EP2195042A1 (en) 2010-06-16
US11337863B2 (en) 2022-05-24
MX2010003087A (en) 2010-06-23
US20110076313A1 (en) 2011-03-31
EP2195042A4 (en) 2010-09-01
EP2195042B1 (en) 2012-11-14
KR20100087096A (en) 2010-08-03
WO2009036571A1 (en) 2009-03-26
US20100268149A1 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
US11337863B2 (en) Antimicrobial gas impregnated devices and methods
US20090255536A1 (en) Biofilm-Inhibiting Catheters and Tubings
Percival et al. Healthcare-associated infections, medical devices and biofilms: risk, tolerance and control
Evans et al. Susceptibility of bacterial biofilms to tobramycin: role of specific growth rate and phase in the division cycle
Bayston et al. Prevention of hydrocephalus shunt catheter colonisation in vitro by impregnation with antimicrobials.
JP4999842B2 (en) Antibacterial composition for inhibiting the growth and proliferation of microbial biofilms on medical devices
US8992590B2 (en) Biocompatibility layer and coated objects
Jang et al. Effect of vancomycin-coated tympanostomy tubes on methicillin-resistant Staphylococcus aureus biofilm formation: in vitro study
CN105254913A (en) Polyester material with antibacterial and biocompatible surface and preparing method and application thereof
Park et al. Antibacterial effect of tea-tree oil on methicillin-resistant Staphylococcus aureus biofilm formation of the tympanostomy tube: an in vitro study
US20100087769A1 (en) Biocidic medical devices, implants and wound dressings
KR102548671B1 (en) Antimicrobial compositions comprising antimicrobial hydrogels effective against mature biofilms
Georgescu et al. Microbial biofilms and implantable hearing aids
US20220226545A1 (en) Methods of coating antimicrobial peptides on the biomaterial and the biomaterial coated thereby
Bayston Biofilms and prosthetic devices
CN114177359B (en) Antibacterial coating and preparation method and application thereof
Zheliba et al. Assessment of the antimicrobial activity of polymer materials with added nanosilica modified by silver compounds
Durmus et al. Fructose enhanced reduction of bacterial growth on nanorough surfaces without using antibiotics
RU2017145630A (en) COMPOSITIONS AND METHODS FOR APPLICATION OF LAMELLARIAN BODIES FOR THERAPEUTIC PURPOSES
Agalar et al. Inhibition of Staphylococcus epidermidis colonization with fusidic acid-impregnated catheters
Guggenbichler Prevention of implant associated nosocomial infections
Extremina Influence of Antimicrobial Agents on the Adhesion of Staphylococcus Epidermidis to Biomaterials

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130827

FZDE Discontinued

Effective date: 20170323